Statements (60)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:vaccine
|
gptkbp:administered_by |
injection
|
gptkbp:approves |
gptkb:2005
|
gptkbp:available_in |
multiple countries
|
gptkbp:average_temperature |
2 to 8 degrees Celsius
|
gptkbp:clinical_trial |
Phase III
|
gptkbp:clinical_use |
booster vaccination
|
gptkbp:contains |
gptkb:diphtheria_toxoid
gptkb:tetanus_toxoid acellular pertussis antigens |
gptkbp:contraindication |
severe allergic reaction to vaccine components
|
gptkbp:dosage_form |
single-dose vial
recommended every 10 years |
gptkbp:formulation |
liquid suspension
|
https://www.w3.org/2000/01/rdf-schema#label |
Boostrix vaccine
|
gptkbp:ingredients |
gptkb:diphtheria_toxoid
gptkb:tetanus_toxoid pertussis antigens |
gptkbp:is_effective_against |
high efficacy against diphtheria
high efficacy against pertussis high efficacy against tetanus |
gptkbp:is_recommended_by |
gptkb:CDC
gptkb:WHO |
gptkbp:is_recommended_for |
adults
adolescents |
gptkbp:is_vulnerable_to |
updated periodically
varies by location public health programs refrigerated FDA approved ongoing studies healthcare provider EMA approved adverse effects monitoring combination vaccine available through pharmacies reduces morbidity and mortality developed from DTP vaccine reduces incidence of disease single dose for adolescents and adults |
gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
gptkbp:market |
ongoing
|
gptkbp:route_of_administration |
intramuscular
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:side_effect |
fatigue
headache muscle pain fever recommended pain at injection site |
gptkbp:target_audience |
adolescents and adults
|
gptkbp:trade |
gptkb:Boostrix
|
gptkbp:used_for |
prevention of diphtheria
prevention of pertussis prevention of tetanus |
gptkbp:vaccine_category |
gptkb:Tdap_vaccine
|
gptkbp:vaccine_funding |
covered by insurance plans
|
gptkbp:vaccine_information |
patient information leaflet
|
gptkbp:bfsParent |
gptkb:Boostrix
|
gptkbp:bfsLayer |
5
|